이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nuheara 과거 수익 실적

과거 기준 확인 0/6

Nuheara의 수입은 연평균 -11.8%의 비율로 감소해 온 반면, Tech 산업은 수입이 연평균 11.6%의 비율로 증가했습니다. 매출은 연평균 4.3%의 비율로 증가해 왔습니다.

주요 정보

-11.8%

수익 성장률

13.0%

EPS 성장률

Tech 산업 성장	11.8%
매출 성장률	4.3%
자기자본 수익률	-246.9%
순이익	-653.3%
최근 수익 업데이트	30 Jun 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Nuheara 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

ASX:NUH 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 23	2	-13	7	4
31 Mar 23	2	-13	8	5
31 Dec 22	2	-14	8	6
30 Sep 22	3	-14	10	6
30 Jun 22	4	-15	11	6
31 Mar 22	5	-15	11	7
31 Dec 21	7	-14	11	7
30 Sep 21	9	-11	11	7
30 Jun 21	11	-8	10	6
31 Mar 21	9	-7	11	3
31 Dec 20	7	-7	11	2
30 Sep 20	5	-9	11	3
30 Jun 20	2	-12	11	3
31 Mar 20	2	-12	11	3
31 Dec 19	2	-12	11	3
30 Sep 19	2	-11	11	2
30 Jun 19	2	-10	11	2
31 Mar 19	3	-9	11	1
31 Dec 18	3	-7	10	0
30 Sep 18	4	-7	9	0
30 Jun 18	4	-7	9	0
31 Mar 18	4	-7	8	0
31 Dec 17	4	-7	7	1
30 Sep 17	3	-6	6	0
30 Jun 17	2	-5	4	0
31 Dec 16	0	-8	2	1
30 Sep 16	0	-8	2	1
30 Jun 16	0	-7	1	1

양질의 수익: NUH 은(는) 현재 수익성이 없습니다.

이익 마진 증가: NUH 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: NUH 은(는) 수익성이 없으며 지난 5년 동안 연간 11.8% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 NUH 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: NUH 은(는) 수익성이 없어 지난 해 수익 성장을 Tech 업계( 7.8% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: NUH 현재 수익성이 없기 때문에 마이너스 자본 수익률( -246.93% )을 갖습니다.

Nuheara 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Nuheara Limited to Report Q2, 2022 Results on Jan 31, 2022

Recent updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Nuheara Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

Nuheara Limited Announces Appointment of Catherine Morgan as Head of Compliance, Regulatory and Legal

New minor risk - Share price stability

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million.

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Insufficient new directors

Nuheara Announces Commercial Availability of HP Hearing PRO OTC Hearing Aid

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.025401 million.

Nuheara Limited Receives US FDA Approval and Launches HP Hearing PRO

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Nuheara Limited Announces the Resignation of Jean-Marie Rudd as CFO

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Nuheara Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Nuheara Limited Welcomes US Food and Drug Administration's Final Ruling, Establishing A Regulatory Category for Over-The-Counter (Otc) Hearing Aids in the United States

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Limited Announces Executive Changes

Nuheara Limited has filed an IPO in the amount of AUD 5 million.

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Submits 510(k) for U.S. FDA Clearance

Nuheara Announces Executive Changes

Nuheara Limited Announces Successful Clinical Trial Self-Fitted Hearing Aids

Nuheara Limited to Report Q2, 2022 Results on Jan 31, 2022

Nuheara Clinical Trial and FDA 510(K) Pathway Update

We Think Nuheara (ASX:NUH) Needs To Drive Business Growth Carefully

Nuheara Limited Provides Update on Clinical Trial and Pathway to FDA 510(K) Approval

Is Nuheara (ASX:NUH) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.011 loss in FY 2020)

Nuheara Limited Receives U.S. FDA Registration and Hearing Aid Device Listing

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in 1H 2020)

What Can We Make Of Nuheara's (ASX:NUH) CEO Compensation?

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 11.5 million.

Nuheara Limited announced that it expects to receive AUD 11.5 million in funding

Nuheara Limited Appoints Warwick Sauer as Director

Is Nuheara (ASX:NUH) Using Debt In A Risky Way?

Nuheara Receives $2 Million Phase II Works with HP Inc

Full year earnings released - AU$0.011 loss per share

Nuheara Limited announced that it has received funding

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기